Kintara Therapeutics, Inc.
12707 High Bluff Drive, Suite 200
San Diego, CA 92130
March 30, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Kintara Therapeutics, Inc. (the “Company”) |
Registration Statement on Form S-3 (File No. 333-254662)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on April 1, 2021, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
March 30, 2021
Page 2
| Very truly yours, | ||
| KINTARA THERAPEUTICS, INC. | ||
| By: | /s/ Scott Praill | |
| Name: | Scott Praill | |
| Title: | Chief Financial Officer | |
- 2 -
